Literature DB >> 19939865

Review: The biological basis of antipsychotic response in schizophrenia.

James M Stone1, Marie Raffin, Paul Morrison, Philip K McGuire.   

Abstract

Schizophrenia is a severe mental illness affecting approximately 1% of the population worldwide. Antipsychotic drugs are effective in symptom control in up to two-thirds of patients, but in at least one-third of patients the response is poor. The reason for this is not clear, but one possibility is that good and poor responders have different neurochemical pathologies, and may therefore benefit from different treatment approaches. In this selective review we summarise research findings investigating the biological differences between patients with schizophrenia who show a good or a poor response to treatment with antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19939865     DOI: 10.1177/0269881109106959

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  17 in total

Review 1.  Is rational antipsychotic polytherapy feasible? A selective review.

Authors:  Rune Andreas Kroken; Erik Johnsen
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?

Authors:  Stephen M Lawrie; Bayanne Olabi; Jeremy Hall; Andrew M McIntosh
Journal:  World Psychiatry       Date:  2011-02       Impact factor: 49.548

3.  Functional dysconnectivity of the limbic loop of frontostriatal circuits in first-episode, treatment-naive schizophrenia.

Authors:  Pan Lin; Xiaosheng Wang; Bei Zhang; Brian Kirkpatrick; Dost Öngür; James J Levitt; Jorge Jovicich; Shuqiao Yao; Xiang Wang
Journal:  Hum Brain Mapp       Date:  2017-11-02       Impact factor: 5.038

4.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

Review 5.  Drug models of schizophrenia.

Authors:  Hannah Steeds; Robin L Carhart-Harris; James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2015-02

6.  Effects of ketamine on brain function during response inhibition.

Authors:  M Steffens; C Neumann; A-M Kasparbauer; B Becker; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Psychopharmacology (Berl)       Date:  2018-10-24       Impact factor: 4.530

7.  Effects of ketamine on brain function during smooth pursuit eye movements.

Authors:  M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger
Journal:  Hum Brain Mapp       Date:  2016-11       Impact factor: 5.038

8.  Using Intermediate Cognitive Endpoints to Facilitate Translational Research in Psychosis.

Authors:  Gary Gilmour; Francois Gastambide; Hugh M Marston; Mark E Walton
Journal:  Curr Opin Behav Sci       Date:  2015-08-01

9.  Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia?

Authors:  James M Stone
Journal:  Ther Adv Psychopharmacol       Date:  2011-02

Review 10.  Brain-imaging studies of treatment-resistant schizophrenia: a systematic review.

Authors:  Elias Mouchlianitis; Robert McCutcheon; Oliver D Howes
Journal:  Lancet Psychiatry       Date:  2016-03-04       Impact factor: 27.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.